{
  "generated": "2025-11-06T07:07:41.547689+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/behavioral/inositol-slee-gen-0056/sleep/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "SLEE-GEN-0056_01",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/inositol-slee-gen-0056-01",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0056-01",
      "citation": "SLEE-GEN-0056_01 (2016); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/inositol-slee-gen-0056-01; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "SLEE-GEN-0056_02",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/inositol-slee-gen-0056-02",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0056-02",
      "citation": "SLEE-GEN-0056_02 (2017); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/inositol-slee-gen-0056-02; Adverse Events: None reported."
    },
    {
      "study_id": "SLEE-GEN-0056_03",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/inositol-slee-gen-0056-03",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0056-03",
      "citation": "SLEE-GEN-0056_03 (2018); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/inositol-slee-gen-0056-03; Adverse Events: Transient headache."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/inositol-slee-gen-0056-01",
      "study_ids": [
        "SLEE-GEN-0056_01"
      ],
      "primary_study_id": "SLEE-GEN-0056_01",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0056-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/inositol-slee-gen-0056-02",
      "study_ids": [
        "SLEE-GEN-0056_02"
      ],
      "primary_study_id": "SLEE-GEN-0056_02",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0056-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/inositol-slee-gen-0056-03",
      "study_ids": [
        "SLEE-GEN-0056_03"
      ],
      "primary_study_id": "SLEE-GEN-0056_03",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0056-03"
    }
  ],
  "manifest_hash": "sha256:13f45a3393decbe7f03081064692ff6314485b73c3db9b950e358700cb16a81a"
}
